Prime assembly can correct multiple mutations at once, pointing toward universal gene therapies

A groundbreaking genome engineering technique called prime assembly, described in a recent Nature paper, has the potential to revolutionize the field of gene therapy. Prime assembly, an extension of prime editing technology, enables the precise insertion of long DNA fragments into specific locations within living cells. This method could lead to the development of universal gene therapies capable of correcting multiple mutations simultaneously, a significant advancement over current approaches that often require multiple individualized edits for each patient.

The single-step process of prime assembly involves the creation of DNA flaps that serve as tethers, guiding the precise assembly of large DNA pieces to act as permanent gene replacements. This targeted approach is less likely to cause off-target effects, such as unintended gene activation, which can lead to cancerous outcomes. Unlike other gene-editing methods that rely on DNA double-strand breaks or double-strand donors – both of which can cause toxicity and unwanted cell stress – prime assembly avoids these potential hazards.

The technology also works in nondividing cells, which are more common in the body and less prone to unwanted DNA changes. The researchers plan to optimize the delivery of prime assembly components to relevant cells in vivo, such as hematopoietic stem cells for blood disorder therapies. Ultimately, this technology could enable the development of mutation-agnostic therapies to treat a wide range of inherited human diseases, providing more generalizable solutions to genetic disorders.